CyberGene acquires patent for CHD diagnostics test
The patent covers prenatal diagnostics of Chromosome 22q11.2 deletion syndrome. CyberGene's QF-PCR technology offers lower cost, faster results. Regulatory approval expected in 12 months.
See the latest news and media coverage for CyberGene. We track all announcements, press releases, and industry mentions in real time, all in one place.
Diagnostic kit developer for prenatal, pregnancy loss, and male infertility
cybergene.comLast updated
The patent covers prenatal diagnostics of Chromosome 22q11.2 deletion syndrome. CyberGene's QF-PCR technology offers lower cost, faster results. Regulatory approval expected in 12 months.
The event occurs in Vienna from June 10-13, 2022. They invite meetings via sales@cybergene.se. ESHG is a key molecular diagnostics conference.
Cygenex a leader in precision medicine and pharmacogenomic risk optimization today announced the launch of CyPHR TM Cygenex Precision Health Response an AI powered health...
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has entered into an agreement relating to the acquisition of 100 percent...
Life science company Alphahelix's subsidiary Cybergene has entered into an exclusive agreement with Importadora Fabhet for distribution of Cybergene's CE-IVD approved products in Peru. It appears from...
Track CyberGene and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CyberGene and other trending companies.